Literature DB >> 25266402

Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit/hyperactivity disorder.

Soon-Beom Hong1, Ben J Harrison2, Alex Fornito3, Chul-Ho Sohn4, In-Chan Song4, Jae-Won Kim5.   

Abstract

BACKGROUND: Brain frontostriatal circuits have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD). However, effects of methylphenidate on circuit-level functional connectivity are as yet unclear. The aim of the present study was to comprehensively investigate the functional connectivity of major striatal subregions in children with ADHD, including subanalyses directed at mapping cognitive and treatment response characteristics.
METHODS: Using a comprehensive seeding strategy, we examined resting-state functional connectivity of dorsal and ventral subdivisions of the caudate nucleus and putamen in children and adolescents with ADHD and in age- and sex-matched healthy controls.
RESULTS: We enrolled 83 patients with ADHD and 22 controls in our study. Patients showed significantly reduced dorsal caudate functional connectivity with the superior and middle prefrontal cortices as well as reduced dorsal putamen connectivity with the parahippocampal cortex. These connectivity measures were correlated in opposite directions in patients and controls with attentional performance, as assessed using the Continuous Performance Test. Patients showing a good response to methylphenidate had significantly reduced ventral caudate/nucleus accumbens connectivity with the inferior frontal cortices compared with poor responders. LIMITATIONS: Possible confounding effects of age-related functional connectivity change were not excluded owing to the wide age range of participants.
CONCLUSION: We observed a region-specific effect of methylphenidate on resting-state functional connectivity, suggesting the pretreatment level of ventral frontostriatal functional connectivity as a possible methylphenidate response biomarker of ADHD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25266402      PMCID: PMC4275331          DOI: 10.1503/jpn.130290

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  59 in total

1.  Developmental normative data on the test of variables of attention (T.O.V.A.).

Authors:  L M Greenberg; I D Waldman
Journal:  J Child Psychol Psychiatry       Date:  1993-09       Impact factor: 8.982

2.  Regional differences in cerebral perfusion associated with the alpha-2A-adrenergic receptor genotypes in attention deficit hyperactivity disorder.

Authors:  Boong-Nyun Kim; Jae-Won Kim; Hyejin Kang; Soo-Churl Cho; Min-Sup Shin; Hee-Jeong Yoo; Soon-Beom Hong; Dong Soo Lee
Journal:  J Psychiatry Neurosci       Date:  2010-09       Impact factor: 6.186

Review 3.  Differentiating frontostriatal and fronto-cerebellar circuits in attention-deficit/hyperactivity disorder.

Authors:  Sarah Durston; Janna van Belle; Patrick de Zeeuw
Journal:  Biol Psychiatry       Date:  2010-10-20       Impact factor: 13.382

Review 4.  Psychological heterogeneity in AD/HD--a dual pathway model of behaviour and cognition.

Authors:  Edmund J S Sonuga-Barke
Journal:  Behav Brain Res       Date:  2002-03-10       Impact factor: 3.332

5.  Two systems of resting state connectivity between the insula and cingulate cortex.

Authors:  Keri S Taylor; David A Seminowicz; Karen D Davis
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

6.  Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.

Authors:  A Cubillo; A B Smith; N Barrett; V Giampietro; M Brammer; A Simmons; K Rubia
Journal:  Psychol Med       Date:  2013-04-19       Impact factor: 7.723

7.  Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder.

Authors:  Ben J Harrison; Jesus Pujol; Narcis Cardoner; Joan Deus; Pino Alonso; Marina López-Solà; Oren Contreras-Rodríguez; Eva Real; Cinto Segalàs; Laura Blanco-Hinojo; José M Menchon; Carles Soriano-Mas
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

Review 8.  Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.

Authors:  Timothy E Wilens
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

9.  Is aberrant functional connectivity a psychosis endophenotype? A resting state functional magnetic resonance imaging study.

Authors:  Sabin Khadka; Shashwath A Meda; Michael C Stevens; David C Glahn; Vince D Calhoun; John A Sweeney; Carol A Tamminga; Matcheri S Keshavan; Kasey O'Neil; David Schretlen; Godfrey D Pearlson
Journal:  Biol Psychiatry       Date:  2013-06-05       Impact factor: 13.382

10.  Convergent approaches for defining functional imaging endophenotypes in schizophrenia.

Authors:  Godfrey D Pearlson; Vince D Calhoun
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more
  19 in total

1.  Changes in Endogenous Dopamine Induced by Methylphenidate Predict Functional Connectivity in Nonhuman Primates.

Authors:  Rasmus M Birn; Alexander K Converse; Abigail Z Rajala; Andrew L Alexander; Walter F Block; Alan B McMillan; Bradley T Christian; Caitlynn N Filla; Dhanabalan Murali; Samuel A Hurley; Rick L Jenison; Luis C Populin
Journal:  J Neurosci       Date:  2018-12-10       Impact factor: 6.167

2.  Intrinsic Functional Connectivity in Attention-Deficit/Hyperactivity Disorder: A Science in Development.

Authors:  F Xavier Castellanos; Yuta Aoki
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-05

3.  Neural Correlates of Symptom Improvement Following Stimulant Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.

Authors:  Zhen Yang; Clare Kelly; Francisco X Castellanos; Terry Leon; Michael P Milham; Lenard A Adler
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-03-30       Impact factor: 2.576

4.  Predicting Methylphenidate Response in ADHD Using Machine Learning Approaches.

Authors:  Jae-Won Kim; Vinod Sharma; Neal D Ryan
Journal:  Int J Neuropsychopharmacol       Date:  2015-05-10       Impact factor: 5.176

5.  Distinct effects of childhood ADHD and cannabis use on brain functional architecture in young adults.

Authors:  Clare Kelly; F Xavier Castellanos; Olivia Tomaselli; Krista Lisdahl; Leanne Tamm; Terry Jernigan; Erik Newman; Jeffery N Epstein; Brooke S G Molina; Laurence L Greenhill; Steven G Potkin; Stephen Hinshaw; James M Swanson
Journal:  Neuroimage Clin       Date:  2016-09-15       Impact factor: 4.881

6.  Interaction effects of GIT1 and DRD4 gene variants on continuous performance test variables in patients with ADHD.

Authors:  Hyojin Kim; Johanna Inhyang Kim; Haebin Kim; Jae-Won Kim; Bung-Nyun Kim
Journal:  Brain Behav       Date:  2017-08-01       Impact factor: 2.708

7.  ADHD-related sex differences in fronto-subcortical intrinsic functional connectivity and associations with delay discounting.

Authors:  Keri S Rosch; Stewart H Mostofsky; Mary Beth Nebel
Journal:  J Neurodev Disord       Date:  2018-12-13       Impact factor: 4.025

Review 8.  Synaptic Wiring of Corticostriatal Circuits in Basal Ganglia: Insights into the Pathogenesis of Neuropsychiatric Disorders.

Authors:  Hsiao-Ying Kuo; Fu-Chin Liu
Journal:  eNeuro       Date:  2019-06-05

9.  Inconsistency in Abnormal Functional Connectivity Across Datasets of ADHD-200 in Children With Attention Deficit Hyperactivity Disorder.

Authors:  Zhi-Wei Zhou; Yan-Tong Fang; Xia-Qing Lan; Li Sun; Qing-Jiu Cao; Yu-Feng Wang; Hong Luo; Yu-Feng Zang; Hang Zhang
Journal:  Front Psychiatry       Date:  2019-09-27       Impact factor: 4.157

10.  Prediction of sleep side effects following methylphenidate treatment in ADHD youth.

Authors:  Jae Hyun Yoo; Vinod Sharma; Jae-Won Kim; Dana L McMakin; Soon-Beom Hong; Andrew Zalesky; Bung-Nyun Kim; Neal D Ryan
Journal:  Neuroimage Clin       Date:  2019-10-21       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.